CD82 and ovarian carcinoma: All these data corroborate that CD82 is highly glycosylated in ovarian cancer cells and indicate that the reduction of 55 kDa CD82 and the concomitant increase in smaller molecular weight fractions in metastatic ovarian cancer can be attributed to impaired CD82 glycosylation.